Elasomeran - Moderna Therapeutics/National Institute of Allergy and Infectious Diseases
Alternative Names: COVID-19 Vaccine Moderna; Moderna COVID-19 Vaccine; mRNA-1273; mRNA-1273 SARS-CoV-2 vaccine; SARS-CoV-2 RNA vaccine - Moderna Therapeutics; SARS-CoV-2 vaccine - Moderna Therapeutics/National Institute of Allergy and Infectious Diseases; SARS-CoV-2 variant JN.1 vaccine - Moderna Therapeutics; SARS-CoV-2 variant KP.2 vaccine - Moderna Therapeutics; SPIKEVAX; SPIKEVAX-X; SPIKEVAX-XBB.1.5; TAK-919Latest Information Update: 03 Sep 2024
At a glance
- Originator Moderna Therapeutics; National Institute of Allergy and Infectious Diseases
- Developer Leiden University Medical Center; Moderna Therapeutics; National Institute of Allergy and Infectious Diseases; Regeneron Pharmaceuticals; Takeda
- Class COVID-19 vaccines; RNA vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed COVID 2019 infections
- Phase III Human papillomavirus infections
Most Recent Events
- 02 Sep 2024 Registered for COVID-2019 infections (In adolescents, In children, In the elderly, In infants, Prevention, In adults) in Taiwan (IM)
- 01 Sep 2024 Preregistration for COVID-2019 infections (In infants, In children, In adolescents, In adults, In the elderly, Prevention) in Taiwan (IM) before September 2024
- 23 Aug 2024 Japan's Ministry of Health, Labour and Welfare approves Elasomeran for SARS-COV-2 Variant JN.1 treatment of COVID-2019 infections in Japan